Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	30362
Country	United Kingdom

Received	2016-09-29 09:16
Peer-Review Started	2016-10-07 20:45
To Make the First Decision	2016-12-01 14:16
Return for Revision	2016-12-06 19:07
Revised	2017-01-05 18:00
Second Decision	2017-03-15 17:26
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2017-03-24 10:27
Articles in Press	2017-03-24 10:27
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-07-04 01:33
Publish the Manuscript Online	2017-07-12 06:47

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Emerging molecular targets and therapy for cholangiocarcinoma
Manuscript Source	Invited Manuscript
All Author List	Hamzeh Kayhanian, Elizabeth C Smyth and Chiara Braconi
Funding Agency and Grant Number
Corresponding Author	Dr. Elizabeth C Smyth, Department of Gastrointestinal Oncology, Royal Marsden Hospital, London and Surrey SM2 5PT, United Kingdom. elizabeth.smyth@rmh.nhs.uk
Key Words	Cholangiocarcinoma; biliary tract cancer; targeted therapy; immunotherapy; mutation; molecular; microenvironment; stroma; MiRNA
Core Tip	Cholangiocarcinoma (CCA) is a clinically challenging malignancy; it is rare, molecularly hetero­genous and associated with a poor prognosis. Here we review recent data on the genomic landscape of CCA and highlight the results of clinical trials using targeted agents and immunotherapy. We find a number of pro­mising therapeutic agents in development and discuss strategies to improve diagnosis and outcomes in this patient group.
Publish Date	2017-07-12 06:47
Citation	Kayhanian H, Smyth EC, Braconi C. Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2017; 9(7): 268-280
URL	http://www.wjgnet.com/1948-5204/full/v9/i7/268.htm
DOI	http://dx.doi.org/10.4251/wjgo.v9.i7.268

Full Article (PDF)	WJGO-9-268.pdf
Full Article (Word)	WJGO-9-268.doc
Manuscript File	30362-Review.docx
Answering Reviewers	30362-Answering reviewers.pdf
Audio Core Tip	30362-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	30362-Conflict-of-interest statement.pdf
Copyright License Agreement	30362-Copyright assignment.pdf
Peer-review Report	30362-Peer-review(s).pdf
Scientific Misconduct Check	30362-Scientific misconduct check.pdf
Scientific Editor Work List	30362-Scientific editor work list.pdf